Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Birmingham, AlabamaAges 18 years+ - NCT07284420RecruitingPhase 2
Testing empasiprubart with efgartigimod for myasthenia gravis
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Carlsbad, CaliforniaAges 18 years+ - NCT07294170Recruiting
Testing Multiple Treatments for Myasthenia Gravis
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Carlsbad, CaliforniaAges 18 years+ - NCT06252649RecruitingPhase 3
Study of new drug combo for KRAS G12C colorectal cancer
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
Chandler, ArizonaAges 18 years+ - NCT07032662RecruitingPhase 2
Testing Imeroprubart for adults with CIDP
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
Tucson, ArizonaAges 18 years+ - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Birmingham, AlabamaAges Any age - NCT07601425RecruitingPhase 1/Phase 2
ATV-1601 Treatment for Hereditary Hemorrhagic Telangiectasia
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
Boston, MassachusettsAges 18 years+ - NCT07089875RecruitingPhase 3
Testing dotinurad vs allopurinol for people with gout
This study compares a new gout medicine called dotinurad to the common medicine allopurinol. It is for people who have had gout for at least a year, have had at least 2 gout attacks in the last year, and are already taking a stable dose of allopurinol but still have high uric acid levels.
Birmingham, AlabamaAges 18–75 - NCT07161544RecruitingPhase 1/Phase 2
Gene therapy for Stargardt disease
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
Phoenix, ArizonaAges 8–55 - NCT07610278RecruitingPhase 2
Blood Pressure and Cholesterol Treatment Study
This study tests a combination of two new medications (QCZ484 and inclisiran) designed to lower both blood pressure and cholesterol levels. You may be a good fit if you have high blood pressure and high cholesterol that isn't fully controlled by current treatments.
Foley, AlabamaAges 18–75 - NCT07535034RecruitingPhase 2
Testing Dotinurad for Gout in People Who Can't Take Other Medications
This trial tests a new drug called dotinurad for gout patients whose standard medications either don't work or cause side effects. Dotinurad works differently by helping your body get rid of uric acid (the substance that causes gout attacks), and the study will see if it safely lowers uric acid levels.
Granada Hills, CaliforniaAges 18–75 - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07492680RecruitingPhase 2
Study of BMS-986504 for solid tumors with MTAP deletion
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
San Francisco, CaliforniaAges 18 years+ - NCT07094113RecruitingPhase 1
AMG 410 alone or with other drugs for KRAS-altered advanced cancers
This study tests a new drug called AMG 410 by itself or with other medicines in people whose cancer has a specific change in the KRAS gene. It is for advanced or metastatic solid tumors that have not responded to standard treatments or who have chosen not to take them.
Duarte, CaliforniaAges 18 years+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Mobile, AlabamaAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT07204938Enrolling by invitationPhase 3
Long-term study of navenibart for hereditary angioedema
This study tests navenibart over a longer period to see if it continues to prevent swelling attacks in people with hereditary angioedema. It is for people who were already in a previous navenibart study.
Scottsdale, ArizonaAges 12 years+ - NCT07039916RecruitingPhase 3
Study of IMVT-1402 for mild to severe generalized myasthenia gravis
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Huntsville, AlabamaAges 18–80 - NCT07732972Recruiting
Brain and nerve effects of spinal cord stimulation study
This study uses special recordings to understand how a temporary spinal cord stimulator (a device that sends mild electrical pulses) changes brain and nerve activity in people with chronic pain or spinal cord injury. It aims to find out how the stimulation helps the nervous system work better.
Hualien CityAges 20–70 - NCT07339722RecruitingPhase 1
Study of LY4515100 in healthy volunteers
This trial tests a new oral medication in healthy volunteers to see how it moves through the body and how safe it is. Taking part helps researchers understand how the drug works before it's studied in people with a certain condition.
Dallas, TexasAges 18–65 - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07146100Recruiting
Long-term follow-up after AHB-137 treatment for hepatitis B
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07609719RecruitingPhase 4
Switching to Subcutaneous Ocrelizumab for Multiple Sclerosis
This study tests a new way to give ocrelizumab—a medicine that treats multiple sclerosis—as an injection under the skin instead of through an IV. It's for people already taking similar MS drugs who want or need to switch treatments.
Birmingham, AlabamaAges 18–65
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.